Jin Medical International Ltd. ZJYL
Company Overview
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury. The company offers wheelchairs and wheelchair components, such as wheels and brakes; oxygen concentrators, bath aids, and rehabilitative devices, as well as infrastructures for shared wheelchairs and other shared health products; oxygen chambers and beauty instruments; and shampoo instruments and nano thermal therapy chambers. It operates in the Mainland China, Japan, the United States, Hong Kong, Singapore, Korea, Australia, and internationally. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. operates as a subsidiary of Jolly Harmony Enterprises Limited.
Why Investors Should Care
Trades at a P/E of 9.9, below the sector median of 27.4.
Recent Developments
- Sep 2025 Revenue of $20.69M (-12.0% YoY); net profit $1.19M.
- Trailing 12 Months Year-on-year growth — revenue -16.5%, earnings -32.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.5%, profit CAGR -23.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.53% |
| 1 Year: | -16.50% |
Compounded Profit Growth
| 5 Years: | -23.93% |
| 1 Year: | -32.00% |
Stock Price Performance
| 1 Year: | -84.56% |
| 6 Months: | -33.11% |
| 3 Months: | -6.16% |
| 1 Month: | +4.76% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.18 · Neutral
P/E of 9.90 is below the sector median of 27.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -23.9% CAGR over 5 years.
- Trading 88.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZJYL Jin Medical International Ltd. | 1.98 | 9.90 | $15.50M | 0.00% | 2.06% | 4.75% | 2.53% | -23.93% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 19.19M | 19.82M | 23.50M | 20.69M |
| Cost of Revenue | - | 12.99M | 13.04M | 14.00M | 14.64M |
| Gross Profit | - | 6.20M | 6.78M | 9.50M | 6.04M |
| Operating Expenses | - | 4.07M | 3.92M | 5.86M | 5.44M |
| Operating Income | - | 2.13M | 2.87M | 3.64M | 608.18K |
| EBITDA | - | 2.49M | 3.09M | 3.98M | 958.86K |
| Interest Expense | 9.49K | - | - | - | - |
| Pretax Income | - | 2.74M | 3.22M | 4.18M | 1.60M |
| Tax Provision | - | 36.11K | 343.71K | 763.88K | 214.57K |
| Net Income | - | 2.71M | 2.88M | 3.68M | 1.19M |
| Diluted EPS | 0.34 | 0.36 | 0.40 | 0.40 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 20.94M | 32.90M | 45.80M | 53.37M |
| Current Assets | - | 18.90M | 31.12M | 42.82M | 44.14M |
| Cash & Equivalents | - | 4.79M | 6.93M | 8.14M | 7.46M |
| Inventory | - | 6.72M | 5.05M | 5.17M | 4.92M |
| Receivables | - | 4.08M | 4.23M | 8.46M | 5.91M |
| Total Liabilities | - | 5.70M | 8.92M | 17.25M | 23.80M |
| Current Liabilities | - | 5.70M | 8.92M | 17.15M | 23.80M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 4.11M | 11.60M | 18.91M |
| Total Equity | - | 15.24M | 23.98M | 28.82M | 29.64M |
| Shares Outstanding | - | 7.75M | 7.80M | 7.83M | 7.83M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 1.58M | 3.11M | -1.21M | 2.90M |
| Investing Cash Flow | - | -120.90K | -7.73M | -9.51M | -10.79M |
| Financing Cash Flow | - | 121.86K | 6.91M | 11.65M | 7.35M |
| Capital Expenditure | - | -40.17K | -113.94K | -1.12M | -6.63M |
| Free Cash Flow | - | 1.54M | 2.99M | -2.33M | -3.73M |
| Net Change in Cash | - | 1.58M | 2.29M | 933.04K | -534.91K |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 32.3% | 34.2% | 40.4% | 29.2% |
| Operating Margin % | - | 11.1% | 14.5% | 15.5% | 2.9% |
| Net Margin % | - | 14.1% | 14.5% | 15.6% | 5.8% |
| ROE % | - | 17.8% | 12.0% | 12.8% | 4.0% |
| ROCE % | - | 14.0% | 12.0% | 12.7% | 2.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Osaic Holdings Inc. | 0.05% | 3.10K | $6.14K |
| 2 | UBS Group AG | 0.02% | 1.22K | $2.42K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZJYL
ZJYL — Frequently Asked Questions
What is the current share price of Jin Medical International Ltd. (ZJYL)?
As of 2026-08-02 19:16 PDT, Jin Medical International Ltd. (ZJYL) trades at $1.98 on NasdaqCM. Its 52-week range is $1.81 to $17.00.
What is the market capitalisation of ZJYL?
Jin Medical International Ltd. (ZJYL) has a market capitalisation of $15.50M on NasdaqCM.
What is the P/E ratio of ZJYL?
ZJYL trades at a trailing price-to-earnings (P/E) ratio of 9.90. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 0.52.
What is the return on equity (ROE) of ZJYL?
ZJYL has a return on equity (ROE) of 4.75%. Its return on capital employed (ROCE) is 2.06%.
Is ZJYL a good stock to buy?
This page provides a data-driven analysis of Jin Medical International Ltd. (ZJYL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.